U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C25H23N5O2S
Molecular Weight 457.547
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENTAMAPIMOD

SMILES

N#CC(C1=NC2=CC=CC=C2S1)C3=NC(OCC4=CC=C(CN5CCOCC5)C=C4)=NC=C3

InChI

InChIKey=XCPPIJCBCWUBNT-UHFFFAOYSA-N
InChI=1S/C25H23N5O2S/c26-15-20(24-28-22-3-1-2-4-23(22)33-24)21-9-10-27-25(29-21)32-17-19-7-5-18(6-8-19)16-30-11-13-31-14-12-30/h1-10,20H,11-14,16-17H2

HIDE SMILES / InChI
Molecular Formula C25H23N5O2S
Molecular Weight 457.547
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27027242 http://www.pharmacodia.com/yaodu/html/v1/chemicals/a438a122ad7b41a2d652eccda5a6711b.html

Bentamapimod (AS602801) a newly developed, orally-active, ATP competitive inhibitor of JNK, which is in phase IIa clinical trials for the treatment of endometriosis. Bentamapimod showed selective cytotoxic activity against serum-cultured cancer cells and cancer stem cells in vitro. It blocks T-cell proliferation and induces apoptosis. Bentamapimod was discovered by Merck Serono. Then PregLem (a member of the Richter Group) acquired worldwide rights in 2010.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Bentamapimod (AS602801) does cross the blood brain barrier, with 98% brain penetration

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1100 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26654972
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENTAMAPIMOD plasma
Papio anubis
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/26654972
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BENTAMAPIMOD plasma
Papio anubis
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY559441
https://www.001chemical.com/chem/541507-14-6
AA Blocks
AA00G3KR
https://www.aablocks.com/goods/Goods/detail?id=AA00G3KR
AbMole Bioscience
M8921
http://www.abmole.com/products/bentamapimod.html
Achemtek
0102-013344
http://www.achemtek.com/848344-36-5
AK Scientific, Inc. (AKSCI)
3453AH
http://www.aksci.com/item_detail.php?cat=3453AH
Alsachim
4632
http://www.alsachim.com/product-C5980-glo.bal-view.html
Ambeed
A793130
https://www.ambeed.com/products/848344-36-5.html
Ambinter
Amb24123242
http://www.ambinter.com/reference/24123242
Angel Pharmatech
AG-10211
http://www.angelpharmatech.com/848344-36-5.html
Ark Pharma Scientific Limited
A-0651
http://www.arkpharmtech.com/product/32602.html
Aurum Pharmatech LLC
W-5369
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5369
Axon MedChem
2002
https://www.axonmedchem.com/product/2002
BioChemPartner
BCP28061
http://www.biochempartner.com/848344-36-5-BCP28061
BioCrick
BCC1369
http://www.biocrick.com/AS-602801-BCC1369.html
BioSynth
J-519665
https://www.biosynth.com/en/products/all-products/products/J-519665.html
BLD Pharm
BD630897
http://www.bldpharm.com/products/848344-36-5.html
BOC Sciences
848344-36-5
https://www.bocsci.com/as-602801-cas-848344-36-5-item-84-182318.html
Boerchem
BC600638
http://www.boerchem.com/?product_43473.html
Chem Scene
CS-0600
http://www.chemscene.com/848344-36-5.html
Chemspace
CSSB00020668829
https://chem-space.com/CSSB00020668829
CSNpharm
CSN18465
https://www.csnpharm.com/products/as-602801.html
DC Chemicals
DC8256
http://www.dcchemicals.com/product_show-AS_602801_Bentamapimod_.html
eNovation Chemicals
D371781
http://www.enovationchem.com/productDetails.asp?productID=D371781
eNovation Chemicals
D501780
https://www.enovationchem.com/ProductDetails.asp?ProductID=D501780
eNovation Chemicals
Y0974359
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0974359
Excenen
EX-A1361
http://www.excenen.com/searchresultlist.php?id=848344-36-5
Hairui
HR117062
http://www.hairuichem.com/en/product/848344-36-5.html
Lab Network
LN01342136
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01342136
MedChem Express
HY-14761
https://www.medchemexpress.com/AS-602801.html
Molcore
MC559441
https://www.molcore.com/product/541507-14-6
MolPort
MolPort-028-720-362
https://www.molport.com/shop/molecule-link/MolPort-028-720-362
MuseChem
I005085
https://www.musechem.com/product/I005085.html
Renno Tech
RL05217
http://www.rennotech.com/product_show.asp?id=5466
Selleck Chemicals
S8867
http://www.selleckchem.com/products/bentamapimod.html
Smolecule
S520775
http://www.smolecule.com/products/s520775
Sun-shine Chemical
AS 602801
http://www.sun-shinechem.com/Details/AS%20602801/2259/848344-36-5.html
Synblock Inc
SB17178
http://www.synblock.com/product/848344-36-5.html
THE BioTek
bt-261365
https://www.thebiotek.com/product/inhibitors/bt-261365
Vesino Industrial Co Ltd
VA12043
http://www.vsnchem.com/goto/product/51360/
PubMed

PubMed

TitleDatePubMed
Patents

Patents

20030162794
1
20050119277
1
20070088017
1
20070259892
1
20080039377
1
20080051397
1
20080090838
1
20080194520
1

Sample Use Guides

In Vivo Use Guide
320mg/day (160 mg twice a day) for 8 weeks
Route of Administration: Oral
In Vitro Use Guide
Bentamapimod (AS602801) treatment induced cell death and accordingly decreased the number of viable cells in three cell lines (PANC-1, pancreatic cancer; A594, lung cancer; A2780, ovarian cancer) in a dose-dependent manner (7.5 uM being most effective)
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:30:11 GMT 2025
Edited
by admin
on Mon Mar 31 18:30:11 GMT 2025
Record UNII
TT3L4B4U0N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENTAMAPIMOD
INN   WHO-DD  
INN  
Official Name English
AS-602801
Preferred Name English
AS602801
Code English
bentamapimod [INN]
Common Name English
2-(1,3-BENZOTHIAZOL-2-YL)-2-(2-((4-((MORPHOLIN-4-YL)METHYL)PHENYL)METHOXY)PYRIMIDIN-4-YL)ACETONITRILE
Systematic Name English
PGL5001
Code English
Bentamapimod [WHO-DD]
Common Name English
PGL-5001
Code English
Classification Tree Code System Code
NCI_THESAURUS C2149
Created by admin on Mon Mar 31 18:30:11 GMT 2025 , Edited by admin on Mon Mar 31 18:30:11 GMT 2025
Code System Code Type Description
FDA UNII
TT3L4B4U0N
Created by admin on Mon Mar 31 18:30:11 GMT 2025 , Edited by admin on Mon Mar 31 18:30:11 GMT 2025
PRIMARY
CAS
848344-36-5
Created by admin on Mon Mar 31 18:30:11 GMT 2025 , Edited by admin on Mon Mar 31 18:30:11 GMT 2025
PRIMARY
INN
8919
Created by admin on Mon Mar 31 18:30:11 GMT 2025 , Edited by admin on Mon Mar 31 18:30:11 GMT 2025
PRIMARY
PUBCHEM
10195250
Created by admin on Mon Mar 31 18:30:11 GMT 2025 , Edited by admin on Mon Mar 31 18:30:11 GMT 2025
PRIMARY
EPA CompTox
DTXSID401005116
Created by admin on Mon Mar 31 18:30:11 GMT 2025 , Edited by admin on Mon Mar 31 18:30:11 GMT 2025
PRIMARY
CHEMBL
CHEMBL3545213
Created by admin on Mon Mar 31 18:30:11 GMT 2025 , Edited by admin on Mon Mar 31 18:30:11 GMT 2025
PRIMARY
SMS_ID
300000036960
Created by admin on Mon Mar 31 18:30:11 GMT 2025 , Edited by admin on Mon Mar 31 18:30:11 GMT 2025
PRIMARY
NCI_THESAURUS
C87441
Created by admin on Mon Mar 31 18:30:11 GMT 2025 , Edited by admin on Mon Mar 31 18:30:11 GMT 2025
PRIMARY
Related Record Type Details
MITOGEN-ACTIVATED PROTEIN KINASE 10
TARGET -> INHIBITOR
IC50
Structure of BENTAMAPIMOD, (S)-
ENANTIOMER -> RACEMATE
MITOGEN-ACTIVATED PROTEIN KINASE 9
TARGET -> INHIBITOR
IC50
MITOGEN-ACTIVATED PROTEIN KINASE 8
TARGET -> INHIBITOR
IC50
Structure of BENTAMAPIMOD, (R)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of BENTAMAPIMOD
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966